|
    ARQT U.S.: Nasdaq

    Arcutis Biotherapeutics Inc.

    Watchlist
    NEW
    Set a price target alert
    ARQTUS
    After Hours
    Last Updated: Dec 8, 2023 7:51 p.m. EST Delayed quote

    $ 2.2600

    0.10 4.63%
    After Hours Volume: 45.34K
    Close Chg Chg %
    $2.1600 -0.0400 -1.82%
    Advanced Charting
    Volume: 1.98M 65 Day Avg: 2.54M
    78% vs Avg
    2.1150 Day Range 2.2200
    1.7600 52 Week Range 18.0400

    Partner Center

    Your Watchlists

    Customize MarketWatch

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    No Saved Watchlists

    Create a list of the investments you want to track.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    ARQT Overview

    Key Data

    • Open $2.2000
    • Day Range 2.1150 - 2.2200
    • 52 Week Range 1.7600 - 18.0400
    • Market Cap $203.87M
    • Shares Outstanding 94.38M
    • Public Float 77.21M
    • Beta 0.98
    • Rev. per Employee $13.75K
    • P/E Ratio N/A
    • EPS -$4.9489
    • Yield N/A
    • Dividend N/A
    • Ex-Dividend Date N/A
    • Short Interest 17.51M 11/15/23
    • % of Float Shorted 22.68%
    • Average Volume 2.54M

    Performance

    5 Day
    • 8.54%
    1 Month
    • 13.39%
    3 Month
    • -70.89%
    YTD
    • -85.41%
    1 Year
    • -87.29%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 7 Full Ratings

    Recent News

    Arcutis Biotherapeutics downgraded to neutral from buy at Mizuho

    Arcutis Biotherapeutics Shares Slide Premarket After Stock Offering

    Stocks to Watch: Knight-Swift, SolarEdge Technologies, Arcutis Biotherapeutics

    Arcutis Biotherapeutics Shares Sink 8.9% On Public Offering

    Arcutis Biotherapeutics Shares Rise Premarket As FDA OKs Zoryve in Young Children

    Arcutis Biotherapeutics Says Eczema Treatment Met Primary Endpoints

    Read full story

    For Nvidia Stock, It’s Game On! Again

    Arcutis Biotherapeutics price target boosted to $61 from $57 at Mizuho

    Read full story

    MDU Resources and AppHarvest Stock See Action From Activist Investors

    Read full story

    Mercury Systems and GMS Stock See Action From Activist Investors

    Read full story

    Community West Bancshares and Funko Stock See Action From Activist Investors

    Arcutis Biotherapeutics started at overweight at Morgan Stanley

    Arcutis Biotherapeutics started at buy with $38 stock price target at Truist

    Read full story

    Activist Investors Make Moves in Fiesta Restaurant, Chipotle Stock

    Read full story

    IPO market braces for first billion-dollar deals of 2020—and Casper won’t be one of them

    Hold Rating on Arcutis Biotherapeutics Amid Declining Prescription Trends

    on TipRanks.com

    Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Axsome Therapeutics (AXSM) and Cytokinetics (CYTK)

    on TipRanks.com

    After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT)

    on Zacks.com

    Polar Capital Holdings Plc Bolsters Portfolio with Arcutis Biotherapeutics Inc Stake

    Polar Capital Holdings Plc Bolsters Portfolio with Arcutis Biotherapeutics Inc Stake

    on GuruFocus.com

    3 Biotech Stocks With Key Catalysts Coming in December

    on InvestorPlace.com

    FMR LLC Reduces Stake in Arcutis Biotherapeutics Inc

    FMR LLC Reduces Stake in Arcutis Biotherapeutics Inc

    on GuruFocus.com

    Analyst Remarks, Loan Agreement Send Arcutis Biotherapeutics (NASDAQ:ARQT) Lower

    on TipRanks.com

    Arcutis Biotherapeutics (ARQT) was downgraded to a Hold Rating at JonesTrading

    on TipRanks.com

    What 8 Analyst Ratings Have To Say About Arcutis Biotherapeutics

    on Benzinga.com

    DraftKings To Rally Over 48%? Here Are 10 Top Analyst Forecasts For Monday

    on Benzinga.com

    Hold Rating on Arcutis Biotherapeutics Inc. Amid Encouraging Q3 Results and Promising Future Expansion Plans

    on TipRanks.com

    Arcutis Biotherapeutics: Strong Q3 Performance and Promising Growth Prospects Justify Buy Rating

    on TipRanks.com

    Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2023 Earnings: Revenue Soars to $38.1 Million

    Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2023 Earnings: Revenue Soars to $38.1 Million

    on GuruFocus.com

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    on Benzinga.com

    Top 5 Health Care Stocks That Are Preparing To Pump In November

    on Benzinga.com

    Earnings Scheduled For November 3, 2023

    on Benzinga.com

    Earnings Outlook For Arcutis Biotherapeutics

    on Benzinga.com

    Down -50.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Arcutis Biotherapeutics, Inc. (ARQT)

    on Zacks.com

    Arcutis Biotherapeutics, Inc. (ARQT) Loses -51.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    on Zacks.com

    MSP Recovery And 3 Other Stocks Under $3 Insiders Are Buying

    on Benzinga.com

    Arcutis Biotherapeutics Inc.

    Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

    Competitors

    Name Chg % Market Cap
    Eli Lilly & Co. 1.66% $567.73B
    AbbVie Inc. 0.89% $263.56B
    Pfizer Inc. 0.52% $162.5B
    Amgen Inc. -0.81% $144.03B
    Regeneron Pharmaceuticals Inc. -1.06% $91.53B
    Takeda Pharmaceutical Co. Ltd. -1.05% ¥6.38T
    Otsuka Holdings Co. Ltd. -2.55% ¥3.03T
    Incyte Corp. -0.87% $12.26B
    Eisai Co. Ltd. -0.55% ¥2.13T